Business Context and Reporting Period
The filing is Landec Corporation’s Form 10-K for the fiscal year ended May 29, 2016. The request metadata identifies Lifecore Biomedical, Inc. and “2015 Q4,” but the provided filing is for Landec Corporation, which owns Lifecore, and reports annual fiscal 2016 results rather than a standalone Lifecore quarterly filing.
Landec operates three reportable segments: Packaged Fresh Vegetables, Food Export, and Biomaterials. The Packaged Fresh Vegetables and Food Export businesses operate through Apio, while the Biomaterials business operates through Lifecore Biomedical. Products include packaged produce using BreatheWay technology and pharmaceutical-grade hyaluronic acid and aseptic manufacturing services.
Financial Highlights
| Metric | Fiscal 2016 | Fiscal 2015 | Change |
|---|---|---|---|
| Revenue | $541.1 million | $539.3 million | Flat |
| Gross profit | $71.0 million | $65.4 million | +8% |
| Gross margin | 13.1% | 12.1% | +1.0 percentage point |
| Operating income/(loss) | $(19.8) million | $18.5 million | Decline |
| Net income/(loss) attributable to common stockholders | $(11.6) million | $13.5 million | Decline |
| Diluted EPS | $(0.43) | $0.50 | Decline |
| Cash flow from operations | $21.8 million | $26.2 million | Down $4.4 million |
| Capital expenditures | $40.9 million | $17.5 million | Increase |
| Cash and equivalents | $9.9 million | $14.1 million | Down $4.2 million |
| Total debt, including current portion | $54.7 million | $42.5 million | Increase |
- Packaged Fresh Vegetables revenue was $423.9 million, down 2%; gross profit was $40.5 million, down 12%.
- Food Export revenue was $64.2 million, down 5%; gross profit was $4.2 million, down 2%, with a 6.5% gross margin.
- Biomaterials revenue was $50.5 million, up 25%; gross profit was $24.1 million, up 65%. Lifecore revenue mix was approximately 55% ophthalmic, 20% orthopedic, and 25% other/non-HA products.
- Research and development expense was $7.2 million, compared with $7.0 million in fiscal 2015. Selling, general and administrative expense increased 24% to $49.5 million.
- The filing reports a $34.0 million impairment of the GreenLine tradename. Excluding this non-cash charge, management described fiscal 2016 as generating approximately $10.1 million of net income before the impairment and related tax benefit.
- The company recorded a $7.4 million income tax benefit, primarily because of the GreenLine impairment and the resulting pretax loss.
- The company held a $62.7 million fair-value investment in Windset, compared with $61.5 million at the prior year-end, and recorded $1.7 million of dividend income and $1.2 million of fair-value gain during fiscal 2016.
Material Changes Versus the Prior Comparable Period
- Revenue was essentially unchanged because Apio revenue declined 2%, offset by 25% growth in Lifecore and higher corporate licensing and R&D revenue.
- Apio experienced severe produce shortages caused by adverse weather, particularly unseasonably warm California conditions. The company incurred approximately $15.6 million of excess produce costs, which more than offset favorable mix from higher-margin salad kits.
- Apio packaged-vegetable unit volumes declined approximately 5%. Food Export volumes also declined approximately 5%, affected by produce shortages and the strong U.S. dollar.
- Lifecore benefited from a $9.7 million increase in development-service revenue and a $4.6 million increase in fermentation revenue. Aseptic revenue declined $4.2 million because of customer inventory-management initiatives.
- Operating expenses increased materially, including higher Apio marketing and product-launch costs, Lifecore bonuses and staffing, and corporate stock-based compensation.
- Capital spending increased substantially to support Apio facility expansion and Lifecore capacity. Property and equipment increased to $120.9 million from $84.5 million.
- Debt increased by approximately $12.1 million, primarily reflecting new equipment and real-property financing. The company remained in compliance with applicable debt covenants at May 29, 2016.
- GreenLine retail products were being converted to the Eat Smart brand. The related strategic decision resulted in the $34.0 million GreenLine tradename impairment; the remaining GreenLine foodservice tradename was valued at $2.0 million.
Liquidity, Debt, Outlook, and Risks
Landec generated $21.8 million of operating cash flow, used $41.6 million in investing activities, and received $15.6 million from financing activities. Management stated that existing cash and operating cash flow were expected to fund operational and capital requirements for at least the next twelve months.
Total debt was $54.7 million, including $8.0 million due within one year. The company also reported $3.5 million outstanding on Apio’s revolving credit facility, with reported availability of $22.6 million, and $9.6 million of availability under Lifecore’s revolving facility, with no Lifecore borrowings outstanding. Contractual obligations totaled approximately $99.9 million, including debt principal, interest, capital and operating leases, and purchase commitments.
No formal quantitative revenue or earnings guidance is provided in the filing. Management’s outlook emphasizes growth in salad kits, new packaged-vegetable products, Lifecore development and aseptic manufacturing services, additional medical applications for hyaluronic acid, and expanded manufacturing capacity.
- Key risks include adverse weather, produce shortages, crop yields, labor and water availability, perishability, and high fixed production costs.
- Customer concentration is significant: the top five customers represented approximately 45% of revenue; Costco represented approximately 20% and Walmart approximately 12%.
- Approximately 31% of fiscal 2016 revenue came from international customers, exposing the company to currency, trade, regulatory, political, and foreign-demand risks.
- Several raw materials and services are sourced from single suppliers, creating potential supply interruption risk.
- Lifecore and its customers depend on FDA and foreign regulatory clearances, quality-system compliance, inspections, and continued product approvals.
- The Windset investment is a Level 3 fair-value measurement based on significant unobservable assumptions, making reported gains and asset values sensitive to valuation inputs.
- Legal matters, including wage-and-hour claims, resulted in a $775,000 charge during fiscal 2016. Management did not expect current proceedings to materially affect the consolidated financial statements, but an unfavorable resolution could affect a particular period.
- The company paid no common-stock dividends and did not repurchase shares during fiscal 2016 or 2015.
Most Important Facts to Verify
- Confirm the intended issuer and period: the supplied filing is Landec Corporation’s fiscal 2016 Form 10-K, not a Lifecore Biomedical standalone filing or a 2015 fourth-quarter report.
- Reconcile the reported net loss with normalized results excluding the $34.0 million GreenLine impairment and related tax benefit.
- Assess whether Apio’s weather-related sourcing costs and volume declines were temporary or indicate ongoing margin and supply-chain pressure.
- Evaluate Lifecore’s revenue growth, development-service pipeline, customer inventory levels, and sustainability of its reported gross-margin improvement.
- Review debt maturities, variable-rate exposure, covenant requirements, guarantees, and the ability to fund $40.9 million-plus annual capital spending.
- Examine the valuation assumptions and liquidity or exit provisions for the $62.7 million Windset investment.
- Monitor customer concentration, produce purchase commitments, regulatory compliance, single-source suppliers, and outstanding legal and tax contingencies.